

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

VOLUNTARY ANNOUNCEMENT

**LEGEND BIOTECH ANNOUNCED NEW 5-YEAR SURVIVAL DATA FOR
CARVYKTI® IN CARTITUDE-1 STUDY FOR MULTIPLE MYELOMA AT 2025
ASCO ANNUAL MEETING**

This is a voluntary announcement made by GenScript Biotech Corporation (the “**Company**”).

Legend Biotech Corporation (“**Legend Biotech**”), an associate of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) on 3 June 2025 (New York time) (after trading hours on 3 June 2025 in Hong Kong) and issued a press release announcing new data from the CARTITUDE-1 study that show long-term outcomes after a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with no maintenance or subsequent myeloma therapy. Notably, one-third of patients with relapsed/refractory multiple myeloma remained progression-free for five years or more. These data were presented as an oral presentation at the 2025 American Society of Clinical Oncology (“**ASCO**”) Annual Meeting (Abstract #7505). CARTITUDE-4 subgroup analyses were also featured in a poster presentation at ASCO that highlighted consistent, durable progression-free and overall survival benefit when compared to the standard of care across cytogenetic risk groups as early as second-line therapy. Preliminary results from Phase 1 LB2102 and Phase 1 LB1908 ongoing dose-escalation studies in solid tumors, specifically lung and gastric cancers respectively, were also be featured in poster presentations at ASCO. For details, please refer to the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000117184325003621/0001171843-25-003621-index.html> and the press release as published on the Legend Biotech’s website available at <https://investors.legendbiotech.com/press-releases>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
GenScript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 4 June 2025

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“**Mr. Robin Meng**”), Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Dr. Li Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (“**Mr. Andy Cheung**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“**Dr. Victor Shi**”).*